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Numerous publications have documented that the immortal cells
grown in three-dimensional (3D) cultures possess physiological
behavior, which is more reminiscent of their parental organ than
when the same cells are cultivated using classical two-dimensional
(2D) culture techniques. The goal of this study was to investigate
whether this observation could be extended to the determination of
LD50 values and whether 3D data could be correlated to in vivo
observations. We developed a noninvasive means to estimate the
amount of protein present in a 3D spheroid from it is planar area
(± 21%) so that a precise dose can be provided in a manner similar to
in vivo studies. This avoided correction of the actual dose given
based on a protein determination after treatment (when some cells
may have lysed). Conversion of published in vitro LC50 data (mM)
for six common drugs (acetaminophen, amiodarone, diclofenac,
metformin, phenformin, and valproic acid) to LD50 data (mg
compound/mg cellular protein) showed that the variation in LD50
values was generally less than that suggested by the original LC50
data. Toxicological analysis of these six compounds in 3D spheroid
culture (either published or presented here) demonstrated similar
LD50 values. Although in vitro 2D HepG2 data showed a poor
correlation, the primary hepatocyte and 3D spheroid data resulted
in a much higher degree of correlation with in vivo lethal blood
plasma levels. These results corroborate that 3D hepatocyte cultures
are significantly different from 2D cultures and are more
representative of the liver in vivo.
Key Words: spheroid culture; drug toxicity; planimetry; protein-
to-drug ratio; in vivo/in vitro correlation; LD50/LC50.
There is an increasing amount of data suggesting that when
cells are grown in three-dimensional (3D) environments (in
suspension, on scaffolds, etc.), they express a number of
physiological characteristics and resemble more closely the
native tissue from which they originated than the same cells
grown in classical two-dimensional (2D) culture flasks. The
reason for this has been suggested to be related to the fact that
3D cell culture allows the cells to develop a more elaborate
extracellular matrix and better intercellular communication (Daus
et al., 2011; Lin et al., 2006; Loessner et al., 2010), and this
leads to a recovery or maintenance of in vivo function (Selden
et al., 2000). Three-dimensional (3D) structure has therefore
been proposed as the missing link, which will provide in vitro
models that sufficiently mimic in vivo conditions (Griffith and
Swartz, 2006; Nelson et al., 2010; Pampaloni et al., 2007).
The data supporting this concept is fragmentary and has
come from many sources. Many of the studies have used
primary cells and these have shown that 3D culture prolongs
crucial liver-like functionality in primary rat (Brophy et al.,
2009; Schutte et al., 2011), porcine (Nelson et al., 2010),
and human hepatocytes (Tostoes et al., 2012). Spheroid
formation maintains cytochrome P450 expression (Adachi
et al., 2011) enhances drug efflux activities (Oshikata
et al., 2011) and preserves (compared with adult liver) gene
expression of several key hepatic markers (including adhesion
molecules, transcription factors, metabolic enzymes including
cytochrome P450, and transporters) (Sakai et al., 2010).
Although most studies have used primary hepatocytes, there
are several reports in the literature that illustrate that immortal
hepatocytes also can recover crucial liver-like functionality and
that this might increase their value for toxicological studies
(Elkayam et al., 2006; Selden et al., 2000; Xu et al., 2003a,b).
In this report, we have extended these studies, addressed
some commonly encountered obstacles and investigated six
commonly used drugs using spheroids constructed from
immortal human C3A hepatocytes.
There are a number of obstacles that make quantitative
toxicology using 3D cultures more complicated than using
2D cultures. The first of these relate to the fact that it is
impossible to count the cells in 3D structures. The second is
that it is difficult to take a representative portion of a 3D
spheroid culture because the culture is ‘‘particulate.’’ Finally,
the third problem is that cells in mature 3D cultures grow
significantly slower than their counterparts in 2D. The doubling
time for the C3A cell line grown in 2D cultures is about 40 h,
whereas in 3D, the same cell line has a doubling time of weeks,
even though the cells are equally metabolically active.
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In order to circumvent these problems, we decided to
normalize our data to the actual amount of protein present, in
a similar manner as is used in toxicity studies in vivo where the
animal is treated with an amount of the compound (typically in
milligrams) correlated to the weight of the animal (kilograms).
Our first challenge was thus to devise a nondestructive means
to relate protein amount to the size of the spheroids and
determine whether it was accurate enough to use. Once this
was achieved, we determined the median lethal dose (LD50) for
six common drugs that are often used for toxicity studies to
determine whether the values obtained using 3D spheroids
could be compared with those obtained in vitro in classical
studies (using either primary hepatocytes or immortal cell
lines) and with in vivo observations of lethal toxicity (e.g., from
overdose cases).
MATERIALS AND METHODS
Cell Culture
The immortal human hepatocyte cell line, HepG2/C3A (American Type
Culture Collection [ATCC] cat. no. CRL-10741, third passage after receipt
from ATCC, Manassas, VA), was thawed from liquid nitrogen storage and left
in standard tissue culture conditions (87.5% Dulbecco’s Modified Eagle’s
Medium (D-MEM) (1 g glucose/l) (Gibco, Carlsbad, CA; Cat. no. 31885-023);
1% non-essential amino acids (Gibco; Cat. no. 11140-035); 10% fetal calf
serum (FCS) (Sigma, St Louis, MO; Cat. no. F 7524); 0.5% penicillin/
streptomycin (Gibco; Cat. no. 15140-122) 1% GlutaMAX (Gibco; Cat. no.
35050-038), 37C, 5% CO2 95% air). To eliminate any effects of storage in
liquid nitrogen or thawing, cells were grown for at least three passages before
starting the experiments, exchanging the medium every 2–3 days.
Standard 2D Culture Conditions
For experiments with cells grown in traditional tissue culture conditions, we
used a customized D-MEM growth medium (87.5% D-MEM (1 g glucose/l)
(Gibco; Cat. no. 31885-023); 1% non-essential amino acids (Gibco; Cat. no.
11140-035); 10% FCS (Sigma; Cat. no. F 7524); 0.5% penicillin/streptomycin
(Gibco; Cat. no. 15140-122) 1% GlutaMAX (Gibco; Cat. no. 35050-038).
Cells were trypsinised (0.05% trypsin/EDTA, Cat. no.: Gibco. 15400-054) for
3 min and sown out into falcon flasks/microtiter plates and cultivated at
37C, 5% CO2 95% air in a humidified incubator. The doubling time for C3A
cells grown under these conditions was 76 h. The cells were allowed to recover
from the seeding stress and grow for 24 h before any treatment.
Three-dimensional Spheroid Culture Conditions
Preparation of spheroids using AggreWell plates. The C3A cell
spheroids have been prepared with use of AggreWell 400 plates (Stemcel
Technologies, Grenoble, France; Cat. no. 27845). Before use, the plates were
washed twice with growth medium (customized D-MEM). In order to remove
all residual air bubbles from the well surface, the plates were prefilled with 0.5
ml of growth medium and centrifuged (3 min with 30003 g). Cells (1.23 106)
were added to each well, and the plates were centrifuged (3 min with 100 3 g)
and left in the AggreWell plate overnight to form spheroids.
Spheroid culture in bioreactors. The spheroids were detached from the
AggreWell plates by gently washing the wells with prewarmed growth
medium. The detached spheroids were collected into a Petri dish, and the
quality of the spheroids checked by microscopy. Compact spheroids were
introduced into bioreactors (MC2 Biotek, Hørsholm, Denmark; Cat. no. 010).
These bioreactors are specially constructed to be easy to open and close and
designed to maintain 100% humidity around the growth chamber. The
spheroids (approximately 300 per bioreactor) were then cultivated at 37C, 5%
CO2 95% air in a humidified incubator for a minimum of 21 days, exchanging
the medium every 2–3 days (Wrzesinski, 2009).
The day when the cells were transferred into the bioreactor is defined as day 0.
An estimated 90% of the medium was changed on day 1 and thereafter three times
a week during the differentiation period. To achieve a stable suspension of
spheroids, the rotation speed of the bioreactors was initially set between 21 and 23
rpm, and it was adjusted to compensate for the growth of the spheroids (and
reached 27–30 rpm on day 21). The density of the spheroid population was
regulated by opening the bioreactor and splitting or removing excess spheroids (this
usually needed to be performed between day 11 and 14). Before use, the spheroid
batch quality was assessed by staining for 3 min with 0.4% Trypan Blue (Gibco;
Cat. no. 15250-061). Batches showing greater than 90% viability were accepted.
Microscopy and Planimetry
Photomicrographs were taken using an Olympus IX81 motorized micro-
scope and an Olympus DP71 camera. Images were transferred to the Olympus
AnalySiS Docu program (Soft Imaging System) and the ‘‘shadow’’ area of
spheroids measured using the ‘‘Fitted Polygon Area’’ function that calculates
the planar surface of the spheroids in lm2.
Drug Treatment
Acetaminophen (APAP), amiodarone, diclofenac, metformin, phenformin,
and valproic acid (VPA) were all purchased from Sigma. Stock solutions were
prepared just before use by dissolving the compound in either growth medium
or dimethyl sulfoxide (DMSO) and diluted into growth media. A control media
was prepared which contained the same concentration of DMSO vehicle
without any compound. The maximum final DMSO concentration in all cases
where DMSO was needed was 0.01%.
Sixty 21-day-old spheroids (corresponding to approximately 15 million cells
or 3 mg protein) were gently pipette (using a cut-tip) into each 10 ml bioreactor
before treatment to provide ample material for analysis. To initiate drug treatment,
the bioreactor rotation was stopped for 30 s to allow the spheroids to settle to the
bottom of the bioreactor. Ninety percent of the media volume was exchanged
with media containing the compound at concentrations, which gave the final
treatment concentrations given in the figures. Experiments to determine the LD50
were carried out initially using a broad range of drug concentrations (e.g., varying
by a factor of 10) followed by two experiments using a narrow concentration
range (varying typically by a factor of two). For all drugs used except APAP,
each experiment was carried out in duplicate, and adenosine triphosphate (ATP)
was measured in technical triplicates for each sample. For APAP, the experiment
was carried out in triplicate. The LD50 values presented are thus an average of 18
measurements for APAP (n ¼ 6) and 12 for the other 5 compounds (n ¼ 4).
ATP Assay
Cell viability was measured based on their ability to produce ATP. Samples of
the hepatocytes grown either in classical culture conditions (in 96-well microtitre
plates) or as spheroids (usually 2–6 spheroids per assay point) were collected at
appropriate times and transferred to white opaque microtitre plates (Nunc,
Roskilde, Denmark; Cat. no. 165306), the volume of growth medium was
adjusted to 100 ll. The cells were then lysed with 100 ll of lysis buffer
(CellTiter-Glo luminescent cell viability assay, Promega, Fitchburg, WI; Cat. no.
G7571) and shaken in the dark for 20 min before the luminescence was measured
in a FLUOstar OPTIMA (BMG Labtech, Ortenberg, Germany) using the
following parameters: one kinetic window, 10 measurement cycles with 0.3 s of
measurements interval time, 2 s delay per measurement, additional 0.5 s delay per
position change (repeated twice for each measured plate). Replicates were
performed as described under ‘‘Drug Treatment.’’ The data was normalized with
reference to a standard curve for ATP and to the untreated control.
Protein Determination
In order to correlate the shadow area of the spheroid to its protein content,
the latter was determined using the fluorescence-based ProStain Protein
Quantification Kit (Active Motif, Inc., La Hulpe, Belgium; Cat. no. 15001)
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according to the manufacturer’s instructions. All data was expressed as
a function of the amount of protein present.
RESULTS
Spheroids were initiated by sowing 1.2 million freshly
trypsinized human hepatocyte C3A cells into individual wells
of an AggreWell plate, centrifuging and leaving them to adhere
to each other overnight. Thereafter, they were released into
suspension as described and grown in rotating bioreactors for
21 days to reach maturity (Fig. 1A). At various stages,
spheroids were selected from the culture, photographed at both
34 and 310 magnification and then their protein content
determined. Protein determination was carried out on either
pairs or quadruplets of spheroids (Fig. 1B). The boundary of
each spheroid was identified on the digital images using the
‘‘Fitted Polygon Area’’ function in the program (Fig. 1B) to
calculate the planimetric area of each spheroid. This area was
determined for at least 170 spheroids at each magnification for
both pairs and quadruplicates.
Comparison of the planimetric area and protein content of
the spheroids demonstrated a clear correlation with an accept-
able SD (of 21%) to be used as a working tool (Fig. 2).
Essentially, the results (with similar accuracies) were obtained
using either 2 or 4 spheroids or using either 34 or 310 optical
magnification (not shown) indicating that either magnification
or number of spheroids could be used interchangeably.
This noninvasive approach allowed us to estimate and adjust
the protein content of the bioreactor before assaying the toxicity of
various compounds so that it was possible to treat a predetermined
number of cells with a given amount of compound.
In order to assess whether cells in 3D cultures respond in
a similar way to treatment with toxic compounds, mature
differentiated spheroids were treated with six different com-
pounds and their total cellular ATP content measured as
a measure of their viability. The six compounds were selected
to be physiologically diverse so that the conclusions of the
analysis would be more representative of toxicity.
Thus, they were selected on the basis that there was suitable
LC50 data available in the literature; that they were metabolized
by different cytochrome P450 enzymes, have different half-
lives; and that they had their beneficial effects on different
target organs (Table 1).
Mature 21-day-old differentiated spheroids were treated with
different concentrations of the compounds and their total
cellular ATP content measured as a measure of their viability.
The LC50 and LD50 results obtained by treating the 3D
spheroids with increasing concentrations of APAP are shown
in Figure 3. Note that at low APAP concentrations (0.625
and 1.25 mg APAP per mg cellular protein), there was
a reproducible stimulation of ATP production. This may be
a reflection of the cells attempt to counter the APAP-induced
toxicity. Interpolation of the graph indicates that the LD50 for
APAP in these conditions was about 20 mg APAP/mg cellular
protein (LC50 40mM APAP) (Table 2).
We determined the LC50 using ATP production in 3D
spheroids in a similar manner for five other compounds
(Table 2). The results are given both as LD50 (mg compound
per mg cellular protein [mg/mg]) and as LC50 (mM) to
facilitate comparison with published data. In the cases of
amiodarone and metformin, cellular ATP production was
slightly increased at low compound concentrations in
a manner similar to that seen for APAP, whereas this was
not seen for diclofenac, phenformin, and VPA.
DISCUSSION
There is an increasing amount of evidence showing that
when primary cells are grown in 3D culture, they retain
physiological attributes for longer compared with when the
same cells are grown using classical (2D) cell culture
FIG. 1. (A) Photograph of a bioreactor showing 21-day-old spheroids. The
lines visible on the gas exchange membrane are 1 mm apart. (B) Enlarged
photograph of four spheroids. The line delimiting their area can be seen at
various points on their periphery and has been highlighted on the top left
spheroid. Scale bar ¼ 0.5 mm.
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FIG. 2. Correlation between spheroid planar size and their protein content.
Spheroids of different ages were photographed and then their protein content
determined using the ProStain Protein Quantification Kit. The area of the
spheroids was determined using the Olympus AnalySiS Docu Soft Imaging
System program. The figure shows the data for groups of four spheroids,
photographed with 310 magnification only. SD was 21% of the average area.
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techniques. Despite that immortal cells are transformed and
may contain numerous chromosomal aberrations, it appears
that they are able to recover at least some of these physiological
attributes when grown in 3D, apparently retracing their
differentiation pathway.
Growing cells in 3D culture systems has not yet been widely
adopted. This is presumably because of the additional
challenges in working with 3D cultures that are not present
when using the classical 2D culture systems. Three of these
challenges are related as follows: to the fact that it is impossible
to count the cells in a spheroid; that it is difficult to collect
a representative sample from a spheroid culture; and that
spheroid cultures are characterized by having very high cell
numbers per volume growth media.
In 2D cultures, cells are normally counted during the
trypsinization procedure and then sown out and left for a day or
two to recover before an analysis is carried out. This provides
a fairly accurate estimate of the number of cells (or how much
protein) was used in the analysis (and this estimate can be
confirmed by taking an aliquot for protein determination).
In the 3D spheroid cultures described here, typically the cells
are counted after trypsinization and then spheroids are initiated
and left to mature for 21 days. Because their growth rate falls
rapidly during this extended period, it is difficult to estimate
how many cells (or how much protein) are present in a spheroid
culture. It is also difficult to take a representative aliquot
because, by it is very nature, the spheroid culture is particulate.
This manuscript describes a simple approach to estimating
the number of cells in a spheroid and illustrates that it is
important to take the total number of cells into consideration
when determining LD50 values (something that is normally
done in vivo in animal studies but not normally done in vitro in
cell-based studies when median lethal concentration (LC50)
data is produced).
To further investigate the metabolic capacity of human
immortal hepatocytes grown in 3D, we have determined the
LD50 of six commonly used compounds (APAP, amiodarone,
diclofenac, metformin, phenformin, and VPA). In comparing
our data with published 24 h toxicity studies, we have not paid
TABLE 1
Selection Characteristics of Compounds Chosen for the Determination of LC50 Using 3D Spheroids
Compound
Metabolic cytochrome
(references)
Terminal elimination
half-life (h), (Schulz and
Schmoldt, 2003)
Target tissue
(at therapeutic dose)
APAP 1A2, 2E1, and 3A4 (Hazai et al., 2002;
Manyike et al., 2000)
3 CNS
Amiodarone 3A4 (Zahno et al., 2011) 75 Cardiac cells
Diclofenac 2C9 (Mancy et al., 1999) 1.5 Inflammatory cells
Metformin 3A4 (Choi et al., 2010) 3 Liver
Phenformin 1A1, 2D6 (Boobis et al., 1983;
Granvil et al., 2002)
7 Liver
Valproic acid 4B1 (Rettie et al., 1995) 15 CNS
Note. CNS, central nervous system.
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FIG. 3. APAP LD50 determination as measured by the amount of ATP
present in the cells. The total number of 21-day-old spheroids in a 10 ml
bioreactor was adjusted so that the total cellular protein content was 3 mg. The
spheroids were exposed to different concentrations of APAP for 24 h and their
ATP content determined by the CellTiter-Glo luminescent cell viability assay
from Promega. Data was normalized to a mock-treated control. The experiment
was repeated three times, and duplicate samples were collected from each
bioreactor.
TABLE 2
LD50 and LC50 Values for Six Common Compounds as
Determined by Treating 21-day-old 3D Spheroids for 24 h and
Then Measuring ATP Production
Compound
LD50
(mg compound/mg
cellular protein) LC50 (mM) SD (%)
Acetaminophen (APAP) 20 40 20.1
Amiodarone 0.6 0.26 12.7
Diclofenac 2.8 2.6 13.8
Metformin 2.76 5 14.5
Phenformin 0.02 0.03 8.9
Valproic acid (VPA) 10 18 8.5
Note. n ¼ 6 for APAP and n ¼ 4 for the five other compounds.
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great attention to the different methods used for determining
the LC50 because assay differences were shown to be minimal
for VPA treatment of rat hepatocytes grown in sandwich
cultures (Kiang et al., 2010, 2011) and for tamoxifen treatment
of HepG2 cells (Riss and Moravec, 2004), and no clear
correlation emerged between assay method and LC50 obtained
when analyzing the data (see below).
There are numerous LC50 studies of APAP carried out on
human, rat, mouse primary, or immortal cells. Published LC50
values vary considerably from 0.21 to 28.2mM for human
hepatocytes (Jemnitz et al., 2008; Lin et al., 2012; Riches et al.,
2009; Ullrich et al., 2009); from 7.6 to 25mM for rat hepatocytes
(Jemnitz et al., 2008; Lewerenz et al., 2003; Wang et al., 2002);
from 3.8 to 20mM for mouse hepatocytes (Jemnitz et al., 2008;
Moon et al., 2010; Toyoda et al., 2012); and from 0.14 to
29.8mM for cell lines (Huh-7 (Lin et al., 2012), HCC-T (Lin
et al., 2012), C3A (Flynn and Ferguson, 2008), and HepG2
(Miyamoto et al., 2009b; Wang et al., 2002). Initial inspection of
LC50 data presented here suggested that the 3D spheroids were
more resistant to APAP toxicity because an APAP concentration
of about 40mM was necessary to reach 50% lethality. Spheroids
contain many more cells per culture volume than is normally used
in 2D cultures, and one would expect that many cells can
metabolize and detoxify a given dose of APAP faster than few
cells. Therefore, in order to compare the results obtained here
with literature values, published LC50 values (millimolar) were
converted to LD50 values (milligram APAP per milligram cellular
protein or mg/mg). This conversion involved making assumptions
in a few cases where full details were not included in the original
publication. These assumptions were that: all cells (human,
mouse, rat; primary or immortal) contain 0.2 ng soluble protein
per cell; culture vessels were 90% confluent (e.g., that a well in
a 96-well plate contained 30,000 cells); cells were 100% viable;
before treatment, primary cells do not propagate but immortal cell
lines do; immortal cell lines have a 40 h doubling time; and that
during the treatment with compound, no cells propagate. Since the
amount of drug present is also dependent on the reaction volume
(i.e., doubling the volume doubles the amount of drug present),
when not otherwise stated, we assumed that the culture vessels
used in the published literature contained a convenient working
minimum volume (e.g., plates with 96, 48, 24, 12, and 6 wells
have working volumes of 0.1, 0.5, 0.75, 1.4, and 2.7 ml,
respectively). These assumptions correspond to the normal practice
used in many of the cited reports. In some cases, the LC50 value
was interpolated from the appropriate figure in the reference.
A comparison of the LC50 (mM) and the corresponding
LD50 (mg/mg) are shown in Figure 4A for APAP. Data based
on human hepatocytes are indicated with a square (n), rat
hepatocytes with a triangle (:), mouse hepatocytes with
a diamond (¤), human cell lines with a cross (3), rat cell lines
with a plus (1), and 3D spheroid cultures with a circle (d).
Each data point is indicated together with a number, and the
reference is given in the figure legend.
The LD50 for APAP presented here (point 35 in Fig. 4A, 20
mg/mg) using 3D spheroids constructed from C3A cells,
corresponds well with data obtained with spheroids made from
HepG2 cells, where the culture flask was swirled to construct the
spheroids (LD50 10 mg/mg) (Xu et al., 2003a). It also corresponds
reasonably well with the average of the published data for human
hepatocytes (average LD50 ¼ 31 mg/mg) but corresponds less
well when HepG2 cells were grown in classical 2D culture
(average LD50 55 mg/mg). The observation that the LD50 value
for the 3D spheroids is lower than that measured using primary
hepatocytes or using HepG2 cells grown in 2D cultures suggests
that APAP permeability into the spheroid is not a limitation.
Comparison of either all the data or of the data from human,
rat, or mouse hepatocytes or HepG2 showed that the maximum
ratio between the highest and lowest published LC50 values were
usually smaller when the data was expressed as LD50 values
(Table 3). For example, the highest LC50 concentration described
in the literature for APAP is 29.75mM using HepG2 cells (Wang
et al., 2002) and the lowest is 0.137mM using Huh-7 cells (Lin
TABLE 3
Variability of the Published Data for APAP Toxicity in Different Test Systems Comparing the Published LC50 Data
(Expressed as mM) With Its Converted LD50 Values (Expressed as mg APAP per mg Cellular Protein)
Total,
n ¼ 17
Human
Hepatocytes,
n ¼ 4
Rat
Hepatocytes,
n ¼ 3
Mouse
Hepatocytes,
n ¼ 2
HepG2
Cell Line,
n ¼ 2
Other Cell Lines
(any species),
n ¼ 4
3D
Spheroidsa,
n ¼ 2
mM mg/mg mM mg/mg mM mg/mg mM mg/mg mM mg/mg mM mg/mg mM mg/mg
Maximum ratiob 218 20 136 8.5 3.3 3.3 5.3 6.9 10 3.1 147 12 1.5 1.9
Average (mM or mg/mg)c 13 31 17 30 16 32 10 34 16 55 5 23 34 15
Stdsc 11 22 12 21 9 17 9 23 19 39 10 21 9 7
Stds %c 83 70 71 69 57 52 88 69 116 72 186 91 26 45
Note. This comparison is made on the basis of the literature cited in Figure 4A.
aAveraged data of (Xu et al., 2003a) and data presented here.
bMaximum ratio: the ratio between the highest and the lowest published LC50 values.
cThe average, SD, and percentage SD of all published LC50 data within the group defined by the column heading.
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et al., 2012), giving a maximum ratio of 218. When converted to
LD50, the data from these two publications are much closer,
namely 82.32 and 4.13 mg/mg, giving a maximum ratio of only
20. This reduction in variation was usually true within species
and within cell lines and was usually true when the percentage
SD of the average values were compared (Table 3). This
illustrates that the assumptions that were made to convert LC50
to LD50 did not prejudice the data and that in fact, shows that
there is a higher degree of agreement in the published data than
initially meets the eye.
The published data for the other five compounds were also
converted to LD50 values and is shown in Figures 4B–F. As with
APAP, it can be seen that the LC50 concentration was usually
higher for the 3D spheroids (data from this report is shown as
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FIG. 4. Comparison of the published LC50 values for (A) APAP, (B) Amiodarone, (C) Diclofenac, (D) Metformin, (E) Phenformin, and (F) Valproic acid with
their corresponding LD50 values (millimolar compound concentration or as milligrams compound per milligram cellular protein). Squares (n) indicate studies based
on human hepatocytes; open square (h) rhesus monkey; triangles (:), rat hepatocytes; diamonds (¤), mouse hepatocytes; circles (d), spheroids; crosses (3),
HepG2 cell line; and pluses (1), other cell lines. The numbers refer to published references as follows: 1, (Bhandari et al., 2008); 2, (Bort et al., 1998); 3, (Donato
et al., 2009); 4, (Dykens et al., 2008); 5, (Flynn and Ferguson, 2008); 6, (Foretz et al., 2010); 7, (Fulgencio et al., 2001); 8, (Golli-Bennour et al., 2012); 9,
(Gomez-Lechon et al., 2003); 10, (Jemnitz et al., 2008); 11, (Ji et al., 2010); 12, (Kaufmann et al., 2005); 13, (Kiang et al., 2010); 14, (Kingsley et al., 1983); 15,
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27, (Riches et al., 2009); 28, (Toyoda et al., 2012); 29, (Ubl et al., 1994); 30, (Ullrich et al., 2009); 31, (Waldhauser et al., 2008); 32, (Wang et al., 2002); 33, (Xu
et al., 2003a); 34, (Zhou et al., 2001); and 35, data presented in this report.
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point ‘‘35’’ in Fig. 4) than LC50 concentrations reported in the
literature. Once again, this difference disappeared when the LC50
is expressed as LD50 underlining the importance of taking the
number of cells into account when describing toxicity values.
Most LD50 studies of amiodarone have been carried out
using either rat hepatocytes or HepG2 cells, although one study
used rhesus monkey hepatocytes (open square in figure 4B)
(Bhandari et al., 2008). All the data fell within the narrow
range of 0.16–0.98 mg/mg (Fig. 4B).
Xu et al. (2003a,b) constructed spheroids from both rat
hepatocytes and HepG2 cells (separately) and found in-
significant differences in their responses to APAP and
diclofenac (the latter in glucose free, galactose-containing
medium). He concluded that both models were predictive for
chemical-induced hepatic cytotoxicity. The diclofenac LD50
data presented here (2.8 mg/mg) match well with their
observations (0.5 and 1.9 mg/mg for HepG2 and rat
hepatocytes, respectively) (Fig. 4C) (Xu et al., 2003a,b).
Because of the effects of metformin on glucose metabolism,
only studies, which investigated metformin’s toxicity using
alternative carbon sources (e.g., galactose [Dykens et al., 2008]
or pyruvate [Okamoto et al., 2009]), were used for data
analysis. Once again, conversion to LD50 showed that the data
reported here were in close agreement with published values in
the literature (Fig. 4D).
The spheroid LD50 obtained for phenformin was in good
agreement with published values, midway between that seen
for the rat hepatocytes (points 29 and 32) and the HepG2 data
(point 4 in Fig. 4E).
For VPA (Fig. 4F), there was very close agreement between
the average of the rat hepatocyte published data (9.5 mg/mg)
(from Kiang et al. [2010]; Kingsley et al. [1983] and Kiang
et al. [2011]) and the spheroid data (10 mg/mg) and poor
correlation to the averaged cell line data (1.1 mg/mg).
Thus, in general, there is reasonably good agreement
between the data sets, whether cell line, primary hepatocyte,
2D, or 3D culture. However, it remains unclear as to whether
3D cultures are superior to 2D cultures. Therefore, in order to
benchmark the data and evaluate its relevance to assessing
human toxicity in vivo, the data was compared with published
plasma concentrations (lg/ml) which either produced a
comatose state or were lethal in vivo in man (Pollak and
Shafer, 2004; Schulz and Schmoldt, 2003) (Fig. 5). Although
there are numerous reasons why one should not expect a close
correlation (the most obvious reason being that the primary or
immortal cells represent only one type of cell, whereas the
whole organism is constructed of many), the plasma concen-
tration is best measurement for in vivo toxicity available.
In making the comparison to the published in vivo plasma
concentrations, only data based on human hepatocytes were
used in the APAP correlation because it has been shown that
humans and rodents respond differently to APAP (Jemnitz
et al., 2008). Inclusion of all the hepatocyte data would have
had a minimal detrimental effect on the correlation (Table 3).
For all other compounds, data from human and rodents were
treated as equivalent. In addition, it is known that different cell
lines exhibit different abilities to metabolize drugs (e.g.,
diclofenac metabolism in rat primary hepatocytes, rat FaO
cells and human HepG2 cells [Ponsoda et al., 1995], and APAP
metabolism in human hepatocytes, Huh-7. and HCC-T cells [Lin
et al., 2012]). Therefore, the comparisons with conventional 2D
culture were restricted to studies that used the human heptocarci-
noma cell line HepG2. LD50 data from other 3D spheroid studies
(APAP and diclofenac) (Xu et al., 2003a) were included and
pooled with the data presented here and used in the in vitro/in vivo
comparison shown in Figures 4 and 5. No published in vivo lethal
plasma concentration data could be found for diclofenac. Based
on the LD50 data presented here in Table 2, the correlation in
Figure 5 would suggest that the lethal plasma concentration
in vivo would be approximately 60 lg/ml, close to the toxic range
of 50–60 lg/ml given by Schulz and Schmoldt (2003).
Comparison of the HepG2 cell line, in vitro data with the
in vivo lethal plasma concentration data resulted in a poor
correlation (Fig. 5, dashed line, R2 correlation coefficient 0.55),
and the inclusion of all of the cell-line–derived data would have
reduced the correlation further (not shown). The corresponding
comparison of primary hepatocytes with the in vivo data gave
a much better correlation (Fig. 5, dotted line, R2 0.75) and
concurs with the use of primary human hepatocytes for toxicity
determination. The comparison of 3D spheroid data with the
in vivo data also showed a reasonably good correlation (Fig. 5,
solid line, R2 0.86). The fact that 3D spheroids appeared to
correlate better than primary hepatocytes may be due in part to
the fact that the primary hepatocyte data were collected in
different labs and in part that different assays were used to
determine the LD50 values and so the actual degree of
correlation has to be treated with caution.
In conclusion, there are significant differences in the LD50
determined using immortal cells grown in classical 2D culture
techniques when compared with 3D spheroids. Spheroids
constructed from immortal human hepatocytes appear equally
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FIG. 5. Correlation of in vivo plasma concentrations (lg/ml) which induce
either comatose condition or lethal with LD50 concentrations (expressed as mg
compound/mg cellular protein). Squares (n) indicate studies based on hepatocytes
(human, rat, or mouse); circles (d), spheroids; crosses (3), HepG2 cell lines.
APAP, Acetaminophen; Amio, Amiodarone; Metf, Metformin; Phen, Phenformin;
VPA, Valproic acid. There is insufficient data to include other comparisons. No
published in vivo lethal plasma concentration could be found for diclofenac.
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useful as primary human hepatocytes for the determination of
LD50 in vitro.
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